Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2009-01-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Soluble fiber (guar gum) is an indigestible form of sugar that is mostly contained in fruits and vegetables. Soluble fiber can reduce the severity and duration of persistent (constant) diarrhea in children.
The purpose of this research study is to evaluate the many effects of fiber added in the diet of infants with SBS
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fiber Food Introduction in Pediatric Short Bowel Syndrome
NCT05432648
Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?
NCT01891279
The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants
NCT01881256
Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair
NCT02575846
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
NCT01674478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Soluble fiber (guar gum) is an indigestible form of sugar that is mostly contained in fruits and vegetables. Soluble fiber can reduce the severity and duration of persistent (constant) diarrhea in children.
The purpose of this research study is to evaluate the many effects of fiber added in the diet of infants with SBS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fiber-enriched formula then fiber-free formula
Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
guar gum
guar gum (20 g/l of formula) for one week
fiber-free formula then fiber-enriched formula
Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
guar gum
guar gum (20 g/l of formula) for one week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
guar gum
guar gum (20 g/l of formula) for one week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Have Short Bowel Syndrome defined by a history of congenital or surgical loss of intestinal absorptive function resulting in parenteral nutrition dependency of longer than 30 days;
2. Are receiving at least 20% of their caloric needs from enteral nutrition and have been on enteral nutrition for at least 1 week following intestinal resection;
3. Have increased stool output as manifested by watery stools (3-12/day) and increased ostomy output (20-50 cc/kg/day);
4. Have not received antibiotics, probiotics or prebiotics for 2 weeks prior to study entry;
2 Weeks
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
USDA Grand Forks Human Nutrition Research Center
FED
Baylor College of Medicine
OTHER
Arkansas Children's Hospital Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juliana C Frem, MD
Role: PRINCIPAL_INVESTIGATOR
University of Arkansas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CUMG-108061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.